LEGN on Nasdaq
Legend Biotech
American biotechnology company that raised $200 million in 2023 (SEC Form D).1
Price unavailable
Last updated Oct 18, 2026.
Overview
Compare with Amicus Therapeutics, TG Therapeutics or Axsome Therapeutics, or pick any stock.
Financials
From the company’s reports to the SEC. Every number links to the filing it came from.
Key numbers, fiscal 2024
-49.3%Operating margin3
-28.2%Net margin3
120.0%Revenue growth, 20245
-17.0%Return on equity3
0.29×Debt to equity3
-$158.1MFree cash flow3
Where the money goes
Where each dollar of revenue went, fiscal 2024
- Cost of revenue32¢$216.4M
- Research and development62¢$413.5M
- Interest3¢$21.6M
- Income tax3¢$18.9M
Out of $627.2M in revenue.53 The company lost money this year.
Financial statements
No quarterly figures reported.
Every line of the income statement as filed: the last 3 fiscal years, latest first.3
| Period ending | 2025-12-31 | 2024-12-31 | 2023-12-31 |
|---|---|---|---|
| License and other revenue | $84.1M | $144.7M | $35.3M |
| Collaboration revenue | $944.8M | $482.6M | $249.8M |
| Total revenue | $1.0B | $627.3M | $285.1M |
| Cost of collaboration revenue | -$397.1M | -$216.4M | -$144.2M |
| Cost of license and other revenue | -$11.0M | -$18.2M | $0 |
| Research and development expenses | -$414.7M | -$413.5M | -$382.2M |
| Administrative expenses | -$135.8M | -$136.8M | -$106.8M |
| Selling and distribution expenses | -$205.8M | -$147.5M | -$94.2M |
| Other operating expense | -$1.0M | -$4.4M | -$85.8M |
| Operating loss | -$136.5M | -$309.5M | -$528.1M |
| Finance costs | -$21.4M | -$21.6M | -$21.8M |
| Finance income | $40.1M | $61.2M | $54.5M |
| Other (expense)/ income, net | -$164.8M | $111.8M | -$24.8M |
| Loss before tax | -$282.6M | -$158.1M | -$520.2M |
| Income tax (expense)/benefit | -$14.2M | -$18.9M | $1.9M |
| Net loss | -$296.8M | -$177.0M | -$518.3M |
| Basic (in dollars per share) | -$0.81 | -$0.48 | -$1.47 |
| Diluted (in dollars per share) | -$0.81 | -$0.48 | -$1.47 |
| Exchange differences on translation of foreign operations | $190.4M | -$112.5M | $29.6M |
| Other comprehensive income/(loss), net of tax | $190.4M | -$112.5M | $29.6M |
| TOTAL COMPREHENSIVE LOSS | -$106.4M | -$289.5M | -$488.7M |
No quarter-by-quarter statement was filed.
No quarterly figures reported.
Every line of the balance sheet as filed: the last 4 fiscal years (annual) or 4 quarters (quarterly), latest first.3
| Period ending | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Property, plant and equipment | $116.3M | $99.3M | $108.8M | |
| Right-of-use assets | $285.2M | $101.9M | $80.4M | |
| Collaboration prepaid leases | $72.7M | $172.1M | ||
| Other non-current assets | $12.4M | $13.0M | ||
| Total non-current assets | $486.6M | $386.3M | ||
| Collaboration inventories, net | $32.0M | $23.9M | ||
| Trade receivables | $13.1M | $6.4M | ||
| Prepayments, other receivables and other assets | $253.4M | $131.0M | ||
| Time deposits | $46.7M | $835.9M | ||
| Cash and cash equivalents | $901.9M | $286.7M | $1.3B | $786.0M |
| Total current assets | $1.2B | $1.3B | ||
| TOTAL ASSETS | $1.7B | $1.7B | ||
| Trade payables | $83.0M | $38.6M | ||
| Tax payable | $19.2M | $20.7M | ||
| Other payables and accruals | $195.4M | $166.2M | ||
| Lease liabilities | $7.4M | $4.8M | ||
| Contract liabilities | $11.3M | $46.9M | ||
| Collaboration interest-bearing advanced funding | $319.1M | $0 | ||
| Other current liabilities | $1.0M | $500.0K | ||
| Total current liabilities | $636.4M | $277.7M | ||
| Collaboration interest-bearing advanced funding | $0 | $301.2M | ||
| Lease liabilities long term | $87.2M | $44.6M | ||
| Other non-current liabilities | $8.0M | $6.1M | ||
| Total non-current liabilities | $95.2M | $351.9M | ||
| TOTAL LIABILITIES | $731.6M | $629.6M | ||
| Share capital | $100.0K | $100.0K | ||
| Reserves | $1.0B | $1.0B | $1.3B | |
| Total equity | $1.0B | $1.0B | $1.3B | $744.4M |
| TOTAL LIABILITIES AND SHAREHOLDERS' EQUITY | $1.7B | $1.7B |
| Period ending | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Property, plant and equipment | $116.3M | $99.3M | $108.8M | |
| Right-of-use assets | $285.2M | $101.9M | $80.4M | |
| Collaboration prepaid leases | $72.7M | $172.1M | ||
| Other non-current assets | $12.4M | $13.0M | ||
| Total non-current assets | $486.6M | $386.3M | ||
| Collaboration inventories, net | $32.0M | $23.9M | ||
| Trade receivables | $13.1M | $6.4M | ||
| Prepayments, other receivables and other assets | $253.4M | $131.0M | ||
| Time deposits | $46.7M | $835.9M | ||
| Cash and cash equivalents | $901.9M | $286.7M | $1.3B | $786.0M |
| Total current assets | $1.2B | $1.3B | ||
| TOTAL ASSETS | $1.7B | $1.7B | ||
| Trade payables | $83.0M | $38.6M | ||
| Tax payable | $19.2M | $20.7M | ||
| Other payables and accruals | $195.4M | $166.2M | ||
| Lease liabilities | $7.4M | $4.8M | ||
| Contract liabilities | $11.3M | $46.9M | ||
| Collaboration interest-bearing advanced funding | $319.1M | $0 | ||
| Other current liabilities | $1.0M | $500.0K | ||
| Total current liabilities | $636.4M | $277.7M | ||
| Collaboration interest-bearing advanced funding | $0 | $301.2M | ||
| Lease liabilities long term | $87.2M | $44.6M | ||
| Other non-current liabilities | $8.0M | $6.1M | ||
| Total non-current liabilities | $95.2M | $351.9M | ||
| TOTAL LIABILITIES | $731.6M | $629.6M | ||
| Share capital | $100.0K | $100.0K | ||
| Reserves | $1.0B | $1.0B | $1.3B | |
| Total equity | $1.0B | $1.0B | $1.3B | $744.4M |
| TOTAL LIABILITIES AND SHAREHOLDERS' EQUITY | $1.7B | $1.7B |
Cash flow is reported year to date, not quarter by quarter, so there are no separate quarterly figures.
Every line of the cash flow as filed: the last 3 fiscal years, latest first.3
| Period ending | 2025-12-31 | 2024-12-31 | 2023-12-31 |
|---|---|---|---|
| Loss before tax | -$282.6M | -$158.1M | -$520.2M |
| Finance income | -$40.1M | -$61.2M | -$54.5M |
| Finance costs | $21.4M | $21.6M | $21.8M |
| Provision for inventory reserve | -$3.0M | $12.7M | $3.6M |
| Loss on asset impairment | $0 | $4.4M | $0 |
| Depreciation of property, plant and equipment | $9.4M | $10.7M | $10.7M |
| Depreciation of right-of-use assets | $19.5M | $10.7M | $7.8M |
| Fair value loss of warrant liability | $0 | $0 | $85.8M |
| Fair value gains on financial assets measured at fair value change through profit or loss | $0 | $0 | -$700.0K |
| Foreign currency exchange loss/(gain), net | $168.8M | -$109.3M | $28.2M |
| Equity-settled share-based compensation expense | $64.6M | $68.9M | $47.7M |
| Other, net | $1.3M | $1.5M | $1.6M |
| Cash flows from (used in) operations before changes in working capital | -$40.7M | -$198.1M | -$368.2M |
| (Increase)/decrease in trade receivables | -$5.7M | $93.8M | -$99.0M |
| Increase in prepayments, other receivables and other assets | -$126.8M | -$61.7M | -$8.7M |
| Increase in collaboration inventories | -$4.5M | -$17.2M | -$12.7M |
| Increase/(decrease) in trade payables | $44.4M | $14.1M | -$50.2M |
| Increase/(decrease) in other payables and accruals | $36.1M | $43.9M | -$2.7M |
| (Decrease)/increase in contract liabilities, net | -$40.0M | -$49.7M | $100.0M |
| Other assets and liabilities, net | $3.4M | -$4.8M | $600.0K |
| Income tax paid | -$18.4M | -$1.6M | -$700.0K |
| Interest income received | $52.0M | $37.3M | $47.3M |
| Income tax received | $0 | $0 | $1.0M |
| Net cash used in operating activities | -$100.2M | -$144.0M | -$393.3M |
| Purchase of property, plant and equipment | -$28.6M | -$14.1M | -$20.1M |
| Purchase of intangible assets | $0 | $0 | -$2.6M |
| Payment to collaborator for collaboration assets | -$38.8M | -$54.9M | -$98.8M |
| Purchase of financial assets measured at fair value through profit or loss | $0 | -$149.2M | $0 |
| Cash received from withdrawal of financial assets measured at fair value through profit or loss | $0 | $149.2M | $185.0M |
| Purchase of equity instruments | -$5.0M | $0 | $0 |
| Cash receipts of investment income | $0 | $2.5M | $8.9M |
| Addition in time deposits | -$4.5B | -$2.6B | -$4.9B |
| Decrease in time deposits | $5.3B | $1.8B | $4.9B |
| Decrease in pledged deposits | $0 | $500.0K | $900.0K |
| Net cash provided by (used in) investing activities | $709.6M | -$850.6M | $92.9M |
| Proceeds from issuance of ordinary shares for institutional investors, net of issuance cost | $0 | $0 | $234.4M |
| Proceeds from issuance of ordinary shares for follow on public offering, net of issuance costs | $0 | $0 | $349.3M |
| Proceeds from exercise of warrant by warrant holder, net of issuance cost | $0 | $0 | $199.7M |
| Proceeds from exercise of share options | $3.3M | $9.7M | $11.8M |
| Principal portion of lease payments | -$3.6M | -$4.0M | -$3.8M |
| Net cash (used in) provided by financing activities | -$300.0K | $5.7M | $791.4M |
| Effect of foreign exchange rate changes, net | $6.1M | -$2.1M | $700.0K |
| NET INCREASE/(DECREASE) IN CASH AND CASH EQUIVALENTS | $615.2M | -$991.0M | $491.7M |
No quarter-by-quarter statement was filed.
Leadership
Who has led Legend Biotech, and when. Pick a name to see everywhere that person has worked.
Chief executive
201520202025
- Chief executive officerAlan Bash Aug 3, 2026 to Sep 16, 202610
- Chief executive officerIngrid Zhang Sep 16, 2026 to now11
Board members and other officers (9)
- Board memberCorazon (corsee) D. Sanders Mar 18, 2026 to now12
- Board memberDarren Xiaohui Ji Mar 18, 2026 to now13
- Board memberFangliang Zhang Mar 18, 2026 to now14
- Board memberGareth Kung Mar 18, 2026 to now15
- Board memberLi Mao Mar 18, 2026 to now16
- Board memberPatrick John Casey Mar 18, 2026 to now17
- Board memberRobin Meng Mar 18, 2026 to now18
- Board memberTomas J. Heyman Mar 18, 2026 to now19
- Board memberYe Wang Mar 18, 2026 to now20
Timeline
Filings
310 filings to the SEC since October 2021: 6 annual reports, 28 insider forms, 23 large holders, 1 private raises, 252 other. The latest 20:
- Oct 15, 20266-K EDGAR
- Oct 13, 20266-K EDGAR
- Oct 7, 2026S-8 EDGAR
- Oct 1, 20264 EDGAR
- Sep 29, 2026144 EDGAR
- Sep 28, 20264 EDGAR
- Sep 28, 20264 EDGAR
- Sep 28, 20264 EDGAR
- Sep 28, 20264 EDGAR
- Sep 28, 20264 EDGAR
- Sep 28, 20264 EDGAR
- Sep 25, 20266-K EDGAR
- Sep 24, 20266-K EDGAR
- Sep 23, 20264 EDGAR
- Sep 22, 2026144 EDGAR
- Sep 22, 2026144 EDGAR
- Sep 16, 20264 EDGAR
- Sep 16, 20263 EDGAR
- Sep 15, 20266-K EDGAR
- Sep 14, 20266-K EDGAR
The 310 filings since October 2021 can be filtered by form type and year here when JavaScript is on.
Every filing from the last three years, summarized. The full record is on SEC EDGAR.
Insider trades and holders
Large holders
Investors who own more than 5% must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively. 23 such filings since October 2021, the latest 10:
- Aug 6, 2026SCHEDULE 13G/A
- Feb 5, 2026SCHEDULE 13G/A
- Nov 5, 2025SCHEDULE 13G/A
- Aug 6, 2025SCHEDULE 13G/A
- Jun 6, 2025SCHEDULE 13G/A
- Feb 14, 2025SCHEDULE 13G/A
- Feb 12, 2025SCHEDULE 13G/A
- Nov 14, 2024SC 13G/A
- Nov 12, 2024SC 13G/A
- Apr 5, 2024SC 13G/A
From Forms 4 and Schedules 13D and 13G filed with the SEC.
Money raised
Private offerings the company reported to the SEC on Form D.
- Apr 19, 2023Raised $200 million in a private offering of equity Form D: 1 investor so far Form D
Held by these funds
The largest holders among investment managers' 13F reports for the quarter ending Jun 30, 2026, the top 25 of 100. Change is in shares since the quarter before.
| Fund | Shares | Value | Share of the fund | Change |
|---|---|---|---|---|
| Fmr LLC | 29,093,899 | $840.2M | 0.0% | +3,397,159 |
| Deerfield Management Company, L.P. | 8,137,638 | $235.0M | 2.9% | +450,000 |
| Montanova Capital, LLC | 7,070,000 | $204.2M | 4.3% | −511,029 |
| Hhlr Advisors, Ltd. | 5,984,550 | $172.8M | 20.8% | No change |
| BlackRock, Inc. | 4,726,534 | $136.5M | 0.0% | +41,991 |
| Westfield Capital Management Co LP | 4,430,063 | $127.9M | 0.4% | −1,333,412 |
| Assenagon Asset Management S.A. | 3,830,112 | $110.6M | 0.1% | New |
| Goldman Sachs Group Inc | 3,662,315 | $105.8M | 0.0% | +2,198,203 |
| Point72 Asset Management, L.P. | 3,076,124 | $88.8M | 0.1% | −809,893 |
| Kynam Capital Management, LP | 3,001,205 | $86.7M | 4.8% | +1,424,910 |
| Artisan Partners Limited Partnership | 1,559,441 | $45.0M | 0.1% | −695,047 |
| State Street Corp | 1,498,704 | $43.3M | 0.0% | +332 |
| Capital International Investors | 1,420,654 | $41.0M | 0.0% | +772,804 |
| Morgan Stanley | 1,394,531 | $40.3M | 0.0% | +791,284 |
| Soleus Capital Management, L.P. | 1,205,000 | $34.8M | 1.2% | New |
| Davern Capital Partners, LP | 1,191,522 | $34.4M | 5.9% | −123,226 |
| Driehaus Capital Management LLC | 1,158,808 | $33.5M | 0.2% | New |
| Renaissance Technologies LLC | 1,000,200 | $28.9M | 0.0% | +478,400 |
| Ghisallo Capital Management LLC | 1,000,000 | $28.9M | 0.7% | New |
| Matthews International Capital Management LLC | 917,266 | $26.5M | 9.1% | −8,654 |
| Johnson & Johnson | 814,586 | $23.5M | 2.9% | No change |
| IvyRock Asset Management (HK) Ltd | 801,000 | $23.1M | 13.1% | −3,000 |
| EcoR1 Capital, LLC | 800,000 | $23.1M | 1.1% | New |
| Jpmorgan Chase & Co | 766,364 | $22.5M | 0.0% | +478,261 |
| Squarepoint Ops LLC | 769,252 | $22.2M | 0.0% | +289,772 |
13F reports cover disclosed long positions in U.S. stocks only.
Links
- Websitewww.legendbiotech.cn1
- Websitewww.legendbiotech.com1
- X (Twitter)x.com/legendbiotech1
- WikidataQ104188375
- SEC EDGARCIK 1801198
Sources
The numbers on this page point here. Each one links to the record it came from.
- 1WikidataLegend Biotech on Wikidata
- 2SEC EDGARLegend Biotech filings on SEC EDGAR
- 3SEC EDGARLegend Biotech 10-K for fiscal 2025
- 4SEC EDGARLegend Biotech filings on SEC EDGAR
- 5SEC EDGARLegend Biotech 10-K for fiscal 2024
- 6SEC EDGARLegend Biotech 10-K for fiscal 2018
- 7SEC EDGARLegend Biotech 10-K for fiscal 2019
- 8SEC EDGARLegend Biotech 10-K for fiscal 2020
- 9SEC EDGARLegend Biotech 10-K for fiscal 2021
- 10SEC EDGARAlan Bash, Chief executive officer
- 11
- 12
- 13SEC EDGARDarren Xiaohui Ji, Board member
- 14SEC EDGARFangliang Zhang, Board member
- 15SEC EDGARGareth Kung, Board member
- 16SEC EDGARLi Mao, Board member
- 17SEC EDGARPatrick John Casey, Board member
- 18SEC EDGARRobin Meng, Board member
- 19SEC EDGARTomas J. Heyman, Board member
- 20SEC EDGARYe Wang, Board member
- 21